Article
Biochemistry & Molecular Biology
Irene Hana Flones, Harald Nyland, Dagny-Ann Sandnes, Guido Werner Alves, Ole-Bjorn Tysnes, Charalampos Tzoulis
Summary: Early alpha-synuclein aggregation is associated with mitochondrial respiratory complex I (CI) deficiency in neurons of idiopathic Parkinson's disease (iPD), and there is selective loss of neurons affected by both pathologies.
Article
Cell Biology
Alexis Fenyi, Charles Duyckaerts, Luc Bousset, Heiko Braak, Kelly Del Tredici, Ronald Melki
Summary: The study found that fixed tissue from Parkinson's disease and incidental Lewy body disease can promote the aggregation of monomeric alpha Syn into fibrillar assemblies, with significant variations in fibrillar assembly characteristics between regions and shorter lag phases in patients aged 80 and above.
Review
Neurosciences
Kathryn M. Miller, Natosha M. Mercado, Caryl E. Sortwell
Summary: This review highlights the impact of alpha-synuclein on cellular dysfunction in Parkinson's disease and its potential disease-modifying effects, with a special emphasis on the importance of BDNF in this process.
NPJ PARKINSONS DISEASE
(2021)
Review
Neurosciences
Thomas Koeglsperger, Svenja-Lotta Rumpf, Patricia Schliesser, Felix L. Struebing, Matthias Brendel, Johannes Levin, Claudia Trenkwalder, Guenter U. Hoeglinger, Jochen Herms
Summary: Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons. Previous studies have identified cellular and molecular changes that occur before the appearance of Lewy bodies (LBs) in these neurons. Understanding these early pathological events may help in the development of therapeutic and diagnostic strategies for PD.
MOLECULAR NEURODEGENERATION
(2023)
Article
Neurosciences
Sheila M. Fleming, Ashley Davis, Emily Simons
Summary: Parkinson's disease is characterized by the abnormal accumulation of alpha-synuclein in the brain and the loss of dopaminergic neurons. Immunotherapies targeting alpha-synuclein have become a key focus for the development of novel therapies for PD.
Article
Neurosciences
Chang-Ki Oh, Nima Dolatabadi, Piotr Cieplak, Maria T. Diaz-Meco, Jorge Moscat, John P. Nolan, Tomohiro Nakamura, Stuart A. Lipton
Summary: This article investigates the mechanism by which dysregulation of autophagic pathways leads to the accumulation of abnormal proteins and damaged organdies in neurodegenerative disorders. The authors found that pathologic protein S-nitrosylation of p62 is a critical factor for autophagic inhibition and cell-to-cell spread.
JOURNAL OF NEUROSCIENCE
(2022)
Article
Cell Biology
Marta M. Morawska, Carlos G. Moreira, Varun R. Ginde, Philipp O. Valko, Tobias Weiss, Fabian Buechele, Lukas L. Imbach, Sophie Masneuf, Sedef Kollarik, Natalia Prymaczok, Juan A. Gerez, Roland Riek, Christian R. Baumann, Daniela Noain
Summary: Enhancing slow-wave sleep in murine models of Parkinson's disease reduces pathological alpha-synuclein accumulation and may improve disease progression through mechanisms such as promoting glymphatic clearance.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Clinical Neurology
Hideki Oizumi, Kenshi Yamasaki, Hiroyoshi Suzuki, Saki Ohshiro, Yuko Saito, Shigeo Murayama, Yoko Sugimura, Takafumi Hasegawa, Kohji Fukunaga, Atsushi Takeda
Summary: The study suggests that p-alpha Syn accumulation in dermal macrophages is present in patients with IPD and may serve as an important biomarker for the disease. Additionally, the number of dermal macrophages was significantly positively correlated with the number of macrophages with p-alpha Syn deposits in the dermis of IPD patients.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2022)
Review
Clinical Neurology
Ajith Cherian, K. P. Divya, Asish Vijayaraghavan
Summary: Our understanding of the genetic architecture underlying Parkinson's disease has greatly improved in the past 25 years. 5-10% of patients have a monogenic form of the disease. Mutations in autosomal dominant or recessive genes can cause genetic Parkinson's disease. The discovery of mutations in the RIC3 gene provides strong evidence for the role of the cholinergic pathway in the development of Parkinson's disease.
CURRENT OPINION IN NEUROLOGY
(2023)
Article
Clinical Neurology
John Stephen Middleton, Hanna Lynn Hovren, Nelson Kha, Manuel Joseph Medina, Karen Ruth MacLeod, Luis Concha-Marambio, Kendal Jay Jensen
Summary: Parkinson's disease (PD) can be misdiagnosed due to its clinical overlap with atypical parkinsonism. The a-Synuclein (aSyn) Seed Amplification Assay (SAA) has been reported as a potential diagnostic indicator for PD, but its use as a clinical laboratory test has not been validated. This study compares the accuracy of PD clinical diagnosis using the aSyn-SAA test with two different diagnostic inclusion criteria, showing a significant improvement when combined with confirmatory imaging.
JOURNAL OF NEUROLOGY
(2023)
Review
Biochemistry & Molecular Biology
Isaac Perez-Segura, Alberto Santiago-Balmaseda, Luis Daniel Rodriguez-Hernandez, Adriana Morales-Martinez, Hilda Angelica Martinez-Becerril, Paola A. A. Martinez-Gomez, Karen M. M. Delgado-Minjares, Citlaltepetl Salinas-Lara, Irma A. A. Martinez-Davila, Magdalena Guerra-Crespo, Francisca Perez-Severiano, Luis O. O. Soto-Rojas
Summary: Parkinson's disease (PD) is characterized by the misfolding and propagation of alpha-synuclein protein, leading to neurodegeneration. Peroxisome proliferator-activated receptor (PPAR) agonists have shown neuroprotective effects in PD, but their potential anti-alpha-synucleinopathy effects are still unclear. This article analyzes the therapeutic effects of PPARs, specifically PPAR gamma, in PD animal models and clinical trials, and suggests potential mechanisms against alpha-synucleinopathy. Understanding the neuroprotective mechanisms of PPARs will improve the development of disease-modifying drugs for PD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Neurosciences
Xuan Yu, Marine Persillet, Ling Zhang, Yu Zhang, Sun Xiuping, Xianglei Li, Gao Ran, Ludivine S. Breger, Sandra Dovero, Gregory Porras, Benjamin Dehay, Erwan Bezard, Chuan Qin
Summary: The study demonstrated that disease is not transmitted through the bloodstream in a mouse model injected with patient-derived alpha-synuclein aggregates.
NEUROBIOLOGY OF DISEASE
(2021)
Article
Neurosciences
Lilit Gabrielyan, Honghui Liang, Artem Minalyan, Asa Hatami, Varghese John, Lixin Wang
Summary: The study found that male Thy1-alpha-syn mice exhibited more severe behavioral impairments compared to their female counterparts, as well as wild type mice. The differences in behavior were related to higher brain levels of human alpha-syn, rather than sex differences in the altered brain immunoreactivity patterns of alpha-syn and pS129 alpha-syn.
JOURNAL OF ALZHEIMERS DISEASE
(2021)
Article
Pharmacology & Pharmacy
Jyotsna Shankar, K. M. Geetha, Barnabas Wilson
Summary: Parkinson's disease is a chronic progressive neurodegenerative disorder affecting millions globally, with current treatment strategies only offering temporary relief. Nanomedicine is believed to hold promise in improving the treatment outcomes for PD patients in the future.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Engila Khan, Ikramul Hasan, M. Emdadul Haque
Summary: Disease modeling in non-human subjects is crucial for clinical research. Animal models are necessary to replicate the disease process and understand the etiology and pathophysiology. Parkinson's disease, with its progressive nature and various disabilities, has specific pathological hallmarks that involve misfolded protein accumulation and degeneration of neurons. Extensive research has been conducted on Parkinson's disease animal models, including pharmacological and genetic manipulation induction. This review summarizes and discusses commonly used Parkinson's disease animal model systems, as well as their applications and limitations.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)